Previous
Acomplia an anti-obesity drug
Added: (Sat Jul 12 2008)
Title : Acomplia an anti-obesity drug
Acomplia (Rimonabant) is the diet pills or an anti-obesity drug. It was approved in the European Union in June 2006 for the marketing in the European Union only. Acomplia is well known by name Zimulti in USA.
What is Acomplia?
• Acomplia (Rimonabant) is the upcoming and booming in a new group of therapeutic agents alleged Cannabinoid-1 Receptor Blockers (CB1).
• Acomplia is acclimated in the analysis of obesity and accompanying conditions
How does Acomplia work?
• Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle.
• Acomplia switches off the aforementioned brain circuits that accomplish humans hungry if they smoke cannabis.
• CB1 receptor barricade with Acomplia acts to abatement the over activity of the endocannabinoid system (EC system). The EC system is an afresh characterized physiological arrangement that includes receptors such as the CB1 receptor and it has been apparent to play an important role in acclimation physique weight and in authoritative activity balance, as able-bodied as glucose and lipid (or fat) metabolism.
What is Acomplia acclimated for?
• Acomplia diet pills is used to treat overweight and obese patient. Acomplia is advised to take with the combination of diet and exercise.
• Sanofi argues that Acomplia can as well anticipate the risk of cardiovascular disease.
• Patients with around waist circumference (102 cm in men and 88 cm in women) will mostly achieve by taking the diet pills.
Does Acomplia as well aid smoker cessation?
Acomplia has been advised by sanofi-aventis as an aid to quit smoking based on studies for up to one year in over 6,500 smokers motivated to quit smoking.
Acomplia has just been approved in the European Union. Is Acomplia approved in the United States?
• No. Sanofi is still apprehension U.S. business ambitious which it has said could appear by the end of this year.
• U.S. Health authorities accept asked Sanofi for added advice on Acomplia.
• Acomplia accustomed European Union business approval in June 2006.
What are the side-effects of Acomplia?
The common side effects were vomiting and nausea.
Current News and Event on Diet Pills Acomplia
The French Health regulatory body said Friday it has adapted the summary of characteristics of the Sanofi-Aventis (SNY) marketed diet pill Acomplia.
The assay of statistics acquired over the endure year confirms the assurance contour of the drug, conspicuously apropos the risk of ancillary furnishings affiliated to depression.
French health authority acclaimed that the ancillary furnishings arise mainly at the starting of the treatment.
The summary of characteristics of Accomplia now includes new warnings and monitoring recommendations.
For more information please visit : http://www.weightsolution.co.uk